• Users Online: 169
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 4  |  Issue : 2  |  Page : 106-112

Retinol-binding protein 4 as a biomarker of cardiometabolic risk in rheumatoid arthritis


1 Department of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
2 Department of Internal Medicine, Faculty of Medicine for Girls, Al-Azhar University, Cairo; Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt
3 Department of Clinical Pathology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt

Correspondence Address:
MSc Radwa M Fath Allah
Al Zahraa University Hospital, Al-Azhar University
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjamf.sjamf_3_20

Get Permissions

Background Retinol-binding protein 4 (RBP4) has been implicated in the pathogenesis of cardiovascular disease. Higher circulating RBP4 concentrations have been observed in patients with previous clinical arteriosclerosis. RBP4 concentrations are positively related to the early endothelial dysfunction measured using marker flow-mediated dilation in patients with rheumatoid arthritis (RA). Aim This study was done to measure the serum RBP4 level in patients with RA and to assess its clinical relevance to cardiometabolic risk and carotid atherosclerosis in RA. Patients and methods The current study enrolled 50 patients with RA, fulfilling the American College of Rheumatology criteria for the diagnosis of RA, who were divided into three groups: group Ia (severe disease activity), group Ib (moderate disease activity), and group Ic (mild disease activity), together with 40 apparently healthy participants as a control group (group II). Clinical symptoms, disease activity using disease activity score 28, BMI, and blood pressure were assessed. RBP4 levels were measured by enzyme-linked immunosorbent assay technique. Complete blood count; C-reactive protein; fasting blood glucose; lipid profile including total cholesterol, high-density lipoprotein, low-density lipoprotein, and triglycerides; fasting plasma insulin level; calculation of insulin resistance by homeostatic model assessment of insulin resistance; autoantibody profiles; ECG; and carotid artery ultrasound were done. Results RBP4 levels were highly significantly increased in all patients with RA when compared with the control group (P<0.01). There was a statistically significant positive correlation between the level of RBP4 and BMI, carotid intima media thickness (CIMT) RT, CIMT LT, and mean CIMT (r=0.319, 0.292, 0.315, and 0.323 and P<0.05, 0.05, 0.05, and 0.05, respectively). Conclusion Our data suggest that the level of RBP4 was increased in patients with RA compared with control, and increased level of RBP4 is associated with presence of atherosclerosis in patients with RA as demonstrated by CIMT. RBP4 could be used as a marker for early prediction of premature atherosclerosis in patients with RA.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed132    
    Printed0    
    Emailed0    
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal